Veterinary Orodispersible Tablets Market Report 2026

The veterinary orodispersible tablets market size has grown strongly in recent years. It will grow from $1.12 billion in 2025 to $1.21 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to poor medication compliance in companion animals, difficulty in oral dosing of traditional veterinary tablets, limited availability of palatable veterinary formulations, reliance on conventional solid oral dosage forms, lack of advanced drug delivery technologies in veterinary medicine.

The veterinary orodispersible tablets market size is expected to see strong growth in the next few years. It will grow to $1.65 billion by 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising demand for pet-friendly medication formats, increasing adoption of precision drug delivery systems, growth in companion animal healthcare expenditure, advancement in veterinary pharmaceutical formulation technologies, expanding focus on treatment compliance and ease of administration. Major trends in the forecast period include development of taste-masked formulation technologies to improve palatability of veterinary orodispersible tablets, increasing adoption of fast-disintegrating polymer matrices for enhanced drug dissolution in animal oral delivery, rising use of precision-compounded low-dose orodispersible tablets for companion animal therapies, growing integration of advanced excipient engineering to improve stability and disintegration speed in veterinary tablets, expansion of stress-free pet medication delivery systems to improve treatment adherence in animals.

The expanding companion-animal healthcare spending by pet owners is expected to propel the growth of veterinary orodispersible tablets going forward. Companion-animal healthcare spending by pet owners refers to the total expenditure by individuals on veterinary services, preventive care, treatments, and related health products for their pets. The increase in companion-animal healthcare spending by pet owners is growing due to the rising perception of pets as family members, which encourages owners to invest more in preventive care, advanced treatments, and overall well-being. The growing demand for companion-animal healthcare spending by pet owners is driving the adoption of veterinary orodispersible tablets, as these convenient and palatable formulations enhance compliance, ensure accurate dosing, and support the increasing focus on pet wellness and preventive care. For instance, in March 2025, according to the American Pet Products Association, total US pet industry expenditures reached $147 billion in 2023, increasing further to $152 billion in 2024, reflecting continued year-over-year growth. Therefore, expanding companion-animal healthcare spending by pet owners is driving the growth of the veterinary orodispersible tablets market.

The rising pet ownership globally is expected to propel the growth of the veterinary orodispersible tablets market going forward. Pet ownership globally refers to the proportion of households worldwide that keep companion animals, reflecting the prevalence and cultural adoption of pets across different regions. The increase in pet ownership globally is driven by the growing trend of considering pets as family members, which encourages individuals and households to adopt companion animals for companionship, emotional support, and lifestyle enrichment. The rising global pet ownership is driving demand for veterinary orodispersible tablets, as a larger companion-animal population increases the need for convenient, palatable, and easily administered medications to ensure health, compliance, and overall well-being. For instance, in March 2025, according to the American Pet Products Association, currently, 94 million households in the U. S. own at least one pet, representing an increase from 82 million households in 2023. Therefore, rising pet ownership globally is driving the growth of the veterinary orodispersible tablets market.

The expansion of veterinary healthcare infrastructure is expected to propel the growth of the veterinary orodispersible tablets market going forward. Veterinary healthcare infrastructure refers to the network of facilities, trained professionals, and medical resources dedicated to diagnosing, treating, and managing animal health. The growing development of veterinary infrastructure is primarily driven by the increasing rate of pet ownership, as more households across developed nations adopt companion animals, increasing the need for accessible and well-equipped veterinary care facilities. The expansion of veterinary healthcare infrastructure directly boosts demand for advanced and easy-to-administer pharmaceutical dosage forms designed for animals of varying sizes and conditions. For instance, in December 2023, according to the American Veterinary Medical Association, the total number of veterinarians in the United States increased from approximately 124,069 in 2022 to approximately 127,131 in 2023, reflecting an increase of over 3,000 professionals within a single year. Therefore, the expansion of veterinary healthcare infrastructure is driving the growth of the veterinary orodispersible tablets market.

Major companies operating in the veterinary orodispersible tablets market are Zoetis Inc., Elanco Animal Health Incorporated, Ceva Santé Animale S. A., Merck & Co. Inc., Virbac S. A., Phibro Animal Health Corporation, HIPRA S. A., Vetoquinol S. A., Norbrook Laboratories Limited, KRKA d. d. Novo mesto, Intas Pharmaceuticals Limited, Boehringer Ingelheim Animal Health GmbH, Hester Biosciences Limited, Huvepharma EOOD, AdvaCare Pharma, ODT Pharmaceuticals Inc., Provet Pharma Private Limited, Kyoritsu Seiyaku Corporation, Ani Healthcare Private Limited, Vee Remedies Private Limited, Skyec Drugs and Pharmaceuticals Private Limited, Dotcom Pharma Private Limited, Alicanto Vetcare Private Limited, Vetraise Remedies Private Limited, Vetson Healthcare Private Limited.

North America was the largest region in the veterinary orodispersible tablets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary orodispersible tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the veterinary orodispersible tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The veterinary orodispersible tablets market consists of sales of anti-inflammatory tablets, anti-seizure tablets, anti-diabetic tablets, anti-allergic tablets, gastroprotective tablets, antibiotic tablets, cardiovascular support tablets, respiratory support tablets, and immune support tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.